Your browser doesn't support javascript.
loading
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review.
Di Tanna, Gian Luca; Urbich, Michael; Wirtz, Heidi S; Potrata, Barbara; Heisen, Marieke; Bennison, Craig; Brazier, John; Globe, Gary.
Afiliação
  • Di Tanna GL; Statistics Division, The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. gditanna@georgeinstitute.org.au.
  • Urbich M; The George Institute for Global Health, Level 5, 1 King St, Newtown, NSW, 2042, Australia. gditanna@georgeinstitute.org.au.
  • Wirtz HS; Amgen (Europe) GmbH, Global Value & Access, Modeling Center of Excellence, Rotkreuz, Switzerland.
  • Potrata B; Amgen Inc, Global Health Economics, Thousand Oaks, CA, USA.
  • Heisen M; Pharmerit - an OPEN Health company, Rotterdam, The Netherlands.
  • Bennison C; Pharmerit - an OPEN Health company, Rotterdam, The Netherlands.
  • Brazier J; Pharmerit - an OPEN Health company, York, UK.
  • Globe G; Health Economics and Decision Science, University of Sheffield, Sheffield, UK.
Pharmacoeconomics ; 39(2): 211-229, 2021 02.
Article em En | MEDLINE | ID: mdl-33251572
ABSTRACT
BACKGROUND AND

OBJECTIVES:

New treatments and interventions are in development to address clinical needs in heart failure. To support decision making on reimbursement, cost-effectiveness analyses are frequently required. A systematic literature review was conducted to identify and summarize heart failure utility values for use in economic evaluations.

METHODS:

Databases were searched for articles published until June 2019 that reported health utility values for patients with heart failure. Publications were reviewed with specific attention to study design; reported values were categorized according to the health states, 'chronic heart failure', 'hospitalized', and 'other acute heart failure'. Interquartile limits (25th percentile 'Q1', 75th percentile 'Q3') were calculated for health states and heart failure subgroups where there were sufficient data.

RESULTS:

The systematic literature review identified 161 publications based on data from 142 studies. Utility values for chronic heart failure were reported by 128 publications; 39 publications published values for hospitalized and three for other acute heart failure. There was substantial heterogeneity in the specifics of the study populations, methods of elicitation, and summary statistics, which is reflected in the wide range of utility values reported. EQ-5D was the most used instrument; the interquartile limit for mean EQ-5D values for chronic heart failure was 0.64-0.72.

CONCLUSIONS:

There is a wealth of published utility values for heart failure to support economic evaluations. Data are heterogenous owing to specificities of the study population and methodology of utility value elicitation and analysis. Choice of value(s) to support economic models must be carefully justified to ensure a robust economic analysis.
Assuntos

Texto completo: 1 Temas: ECOS / Aspectos_gerais / Avaliacao_economica / Financiamentos_gastos Bases de dados: MEDLINE Assunto principal: Qualidade de Vida / Insuficiência Cardíaca Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Systematic_reviews Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Pharmacoeconomics Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Temas: ECOS / Aspectos_gerais / Avaliacao_economica / Financiamentos_gastos Bases de dados: MEDLINE Assunto principal: Qualidade de Vida / Insuficiência Cardíaca Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Systematic_reviews Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Pharmacoeconomics Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália